Drug Profile
IMP 761
Alternative Names: IMP-761Latest Information Update: 22 Apr 2024
Price :
$50
*
At a glance
- Originator Prima BioMed
- Developer Immutep Limited
- Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
- Mechanism of Action CD223 antigen stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 18 Apr 2024 Immutep Limited and Centre for Human Drug Research enter into agreement for phase I trial for IMP 761 for Autoimmune disorders (In volunteers)
- 31 Oct 2023 Immutep Limited has a patent protection for IMP 761 in Australia (before October 2023)
- 20 Jun 2023 Immutep has patent protection for IMP 761 in USA